VOGLIZEN–M


Each Tablet Contains:
Voglibose IP 0.02 mg
Metformin HCL IP 500 mg

10X10 Rs 85

VOGLIZEN–M

The product contains Voglibose and metformin which is used for treating diabetes and also known as insulin sensitizer which thus decreases the insulin resistance and effectively controls blood sugar. They inhibit gluconeogenesis and enzyme adenylate cyclase. They together reduce the lipid stores and inhibit fat metabolism.

Voglibose belongs to alpha glucosidase inhibitors and belongs to the category of oral antidiabetic drug and promote the breakdown of complex carbohydrates.

Metformin belongs to the class of biguanides which falls under the category of antidiabetic drug. It maintains the plasma fasting insulin levels.

  • In type-2 diabetes mellitus

Mechanism of action-

Voglibose inhibits the alpha glucosidase enzyme which prevents the conversion of complex carbohydrates into the simple sugars and thus prevents their absorption by small intestine.
Metformin causes peripheral utilization of glucose and inhibits production and absorption of glucose.

Pharmacokinetics-

Voglibose-
It is absorbed orally

Metformin-
It is rapidly absorbed
It is 90% bound to plasma proteins
It does not show metabolism
It is excreted unchanged via urine
  • Diarrhoea
  • Flatulence
  • Bloating
  • Abdominal pain
  • Abdominal discomfort
  • Nausea
  • Contraindicated in patients with cardiovascular collapse
  • Contraindicated in diabetic ketoacidosis
  • Ciprofloxacin
  • Citalopram